MRK Merck & Co., Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 310158 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.9%
TTM net income YoY-87.1%
TTM EPS YoY-86.9%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR-19.0%
Margins
Gross margin71.8%
Operating margin—
Net margin3.6%
FCF margin21.9%
EBITDA margin—
Returns
ROE5.1%
ROA1.9%
ROIC (approx.)—
Asset turnover0.51x
Leverage & solvency
Liabilities / assets66.1%
Debt / equity1.20x
Current ratio1.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income7.62x
Accruals ratio-12.4%
Payout ratio341.1%
Capex / revenue5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.09B | $16.61B | $16.29B | $16.40B | $17.28B | $15.81B | $15.53B | $15.62B |
| Cost of revenue | $4.89B | $4.39B | $4.20B | $5.55B | $3.85B | $3.56B | $3.42B | $3.83B |
| Gross profit | $13.19B | $12.21B | $12.09B | $10.85B | $13.42B | $12.25B | $12.11B | $11.80B |
| R&D expense | $4.54B | $9.74B | $12.59B | $3.89B | $4.23B | $4.05B | $3.62B | $4.58B |
| SG&A expense | $2.89B | $2.90B | $2.70B | $2.90B | $2.63B | $2.65B | $2.55B | $2.86B |
| Interest expense | $546.00M | $525.00M | $479.00M | $411.00M | $327.00M | $305.00M | $313.00M | $328.00M |
| Pretax income | $5.56B | -$683.00M | -$3.53B | $3.42B | $6.75B | $5.00B | $5.90B | $4.17B |
| Income tax | $492.00M | $654.00M | $709.00M | $458.00M | $958.00M | $571.00M | $818.00M | $426.00M |
| Net income | $5.07B | -$1.33B | -$4.24B | $2.96B | $5.79B | $4.43B | $5.08B | $3.74B |
| EPS (basic) | 2.05 | -0.54 | -1.72 | — | 2.32 | 1.76 | 2.01 | — |
| EPS (diluted) | 2.04 | -0.54 | -1.72 | — | 2.32 | 1.76 | 2.01 | — |
| Dividends declared per share | 0.85 | 0.85 | 0.85 | 0.85 | 0.81 | 0.81 | 0.81 | 0.81 |
| Weighted avg. shares (diluted) | 2.48B | 2.47B | 2.47B | — | 2.50B | 2.51B | 2.53B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.55B | $6.85B | $5.33B | $14.56B | $18.26B | $8.07B | $8.73B | $13.32B |
| Short-term investments | $100.00M | $292.00M | $375.00M | $0 | $45.00M | $615.00M | $599.00M | $447.00M |
| Receivables | $12.74B | $12.56B | $12.21B | $11.78B | $12.12B | $11.85B | $10.79B | $10.28B |
| Inventory | $6.16B | $6.21B | $6.48B | $6.66B | $6.44B | $6.60B | $6.20B | $6.11B |
| Current assets | $38.94B | $36.68B | $35.02B | $43.52B | $47.56B | $37.06B | $35.50B | $38.78B |
| PP&E, net | $25.90B | $25.74B | $25.43B | $25.32B | $25.64B | $25.24B | $24.79B | $23.78B |
| Goodwill | $21.95B | $21.58B | $21.58B | $21.58B | $21.59B | $21.59B | $21.68B | $21.67B |
| Intangibles | $24.48B | $24.98B | $25.75B | $26.68B | $15.31B | $15.19B | $15.76B | $16.37B |
| Total assets | $132.77B | $129.80B | $128.69B | $136.87B | $129.55B | $117.52B | $115.12B | $117.11B |
| Current liabilities | $28.80B | $27.73B | $26.95B | $28.33B | $28.63B | $26.04B | $25.17B | $28.42B |
| Short-term debt | $4.09B | $2.83B | $2.44B | $2.59B | $1.41B | $1.43B | $1.36B | $2.65B |
| Long-term debt | $49.69B | $51.08B | $46.67B | $46.75B | $39.97B | $33.97B | $33.48B | $34.46B |
| Total debt | $53.78B | $53.91B | $49.12B | $49.34B | $41.37B | $35.40B | $34.84B | $37.11B |
| Total liabilities | $87.83B | $87.82B | $82.75B | $84.20B | $77.64B | $68.46B | $66.72B | $70.73B |
| Shareholders' equity | $44.89B | $41.93B | $45.88B | $52.61B | $51.85B | $48.99B | $48.34B | $46.31B |
| Net debt | $44.23B | $47.06B | $43.79B | $34.77B | $23.11B | $27.33B | $26.11B | $23.79B |
| Cash flow statement | ||||||||
| Operating cash flow | $6.56B | $5.37B | $3.92B | $2.86B | $7.82B | $3.29B | $2.50B | $3.45B |
| Capital expenditure | $1.04B | $893.00M | $991.00M | $1.03B | $987.00M | $764.00M | $1.33B | $937.00M |
| Free cash flow | $5.52B | $4.48B | $2.93B | $1.82B | $6.83B | $2.53B | $1.17B | $2.51B |
| Investing cash flow | -$1.32B | -$5.60B | -$10.21B | -$11.20B | -$283.00M | -$770.00M | -$1.49B | -$1.44B |
| Financing cash flow | -$2.43B | $1.76B | -$2.98B | $4.75B | $2.64B | -$3.56B | -$5.75B | -$3.01B |
| Depreciation & amortization | $726.00M | $599.00M | $581.00M | $1.49B | $532.00M | $518.00M | $502.00M | $522.00M |
| Stock-based compensation | $369.00M | $298.00M | $185.00M | $205.00M | $204.00M | $216.00M | $195.00M | $187.00M |
| Dividends paid | $2.10B | $2.14B | $2.10B | $2.02B | $2.03B | $2.08B | $2.05B | $1.95B |
| Share buybacks | $653.00M | $757.00M | $874.00M | $1.25B | $1.32B | $1.34B | $1.16B | $489.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.